MOTS-c
Mitochondrial ORF of the 12S rRNA Type-C
Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.
The record documents no study in which MOTS-c was given to people: FDA stated in July 2026 that it found no publicly available studies administering MOTS-c free base or acetate to humans, and the only registered interventional trial (NCT07505745, Phase 2a, randomised double-blind placebo-controlled, ~120 adults with prediabetes and overweight) is not finished enrolling. Human data here are observational measurements only, such as exercise-induced rises in muscle and blood MOTS-c and serum levels in 45 people with type 2 diabetes versus 19 controls. The effect claims rest on mouse, rat and cell work, including a 44-rat patent experiment.
Counted on the record: 0 human studies, 0 randomized trials, 0 participants, 1 animal study, 0 lab studies.
No completed study administering MOTS-c as an intervention is recorded. Observational human evidence prevents a zero total-human-study claim.
- FDA
- Not FDA approved for any indication; investigational only. First human interventional trial (Phase 2a, NCT07505745) enrolling in 2026; sold elsewhere as a research chemical labeled not for human use.
- WADA
- Prohibited at all times (WADA List S4.4, metabolic modulators; named as an AMP-activated protein kinase activator). No therapeutic-use exemption is available because there is no approved medical use.
Reference only. Not medical advice.
What can go wrong
Unapproved research chemical with no completed human efficacy or safety trial; the only human interventional study is just enrolling, so the human safety floor and long-term risks are not established. Purchased material is frequently mislabeled or inconsistent in purity.
Talk to a clinician before taking this. The Atlas can tell you what has been studied about MOTS-c. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
A 16-amino acid peptide encoded within mitochondrial DNA, the first mitochondrial-encoded peptide shown to act as a systemic hormone. Levels decline with age and rise sharply with exercise. Published in Cell Metabolism, 2015, and called an "exercise mimetic" in the literature.
A message from two-billion-year-old bacteria living inside your cells.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
MOTS-c is a tiny peptide written into mitochondrial DNA that acts as a metabolic stress signal. Its central action is to switch on AMPK, the cell's fuel gauge, which it does indirectly by interfering with the folate and purine pathways so that a natural AMPK activator accumulates, all without draining the cell's energy. It can also travel into the nucleus to influence gene expression. The downstream effect, strongest in skeletal muscle, is more glucose uptake, more fat burning, better insulin sensitivity and greater metabolic flexibility, the same kind of adaptation the body makes in response to exercise.
- Step 1Oxidative stressIn the rat model, MOTS-c was linked to lower oxidative-stress markers.
- Step 2Dopamine signalingTreated rats showed stronger dopamine-related signals in the striatum.
- Step 3MovementTreated rats performed better in movement tests.
These findings came from an animal experiment reported in a patent, not a human clinical trial.
Sixteen amino acids, encoded outside the cell nucleus.
- Type
- Mitochondrial-derived peptide
- Size
- 16 amino acids
- Origin
- 12S rRNA, mtDNA
- Acts via
- AMPK activation
- Declines
- With age
- Status
- Investigational / gray-market
Mimics A Signal, Not A Workout
MOTS-c is one of the more scientifically interesting molecules in this library, and the honesty is about how far the evidence actually reaches. The "exercise in a bottle" label has a real basis: MOTS-c levels rise in muscle and blood with exercise, the molecule declines with age, and in animals giving it back reproduces a subset of training adaptations and restores metabolic flexibility in aged mice. But two things get glossed over. First, it mimics some of the biochemical signaling of exercise, not the full physiological package, so it is not an exercise replacement. Second, the human evidence is early, inconsistent across populations, and best read as physiology research rather than proven therapy; the one serious attempt to turn a MOTS-c-like peptide into a drug, by the biotech CohBar, did not pan out in the clinic. Strong biology, real rationale, and a product that does not yet exist.
How it is taken
Injection
Human MOTS-c vs Synthetic MOTS-c
Safety in detail
- We hold MOTS-c human data as observation only: levels rise with exercise and fall with age, and the first interventional study is still enrolling.
- MOTS-c activates AMPK and shifts metabolism, so blood sugar warrants monitoring and long-term effects stay unknown.
Children and teenagers
MOTS-c is a metabolic research peptide with no pediatric data, no approval and no rationale for use in anyone under 18. Manipulating a child’s metabolic and AMPK signaling with an unproven, gray-market compound has no justification, and the sourcing risks apply on top. There is no appropriate pediatric use.
What people get wrong
Often saidIt replaces exercise
ActuallyIt mimics some exercise signaling (AMPK activation) in animals. It does not reproduce the full systemic benefits of actually training.
Often saidHuman results are proven
ActuallyHuman trials are at their earliest stage. The mouse-to-human gap in metabolic compounds has historically been enormous.
Who profits, and who pushes back
Longevity research community
Human trials are in earliest stages. No safety floor has been established in healthy people.
Peptide research community
MOTS-c is large and hard to synthesize consistently; independent testing finds many commercial samples degraded or impure.
Dr. David Sinclair
Discussed in the context of mitochondrial biology and aging. Academic framing; commercial longevity interests exist but not in MOTS-c.
Bryan Johnson
Referenced in longevity protocols. Whether it is in the commercial Blueprint line is unconfirmed.
There is no approved MOTS-c product, so the money is the familiar gray-market and clinic mix: research-peptide vendors selling vials, and longevity and metabolic clinics offering it within optimization programs. The instructive commercial note is CohBar, a biotech that built its strategy around mitochondrial-derived peptide drugs including a MOTS-c analog, and whose clinical setbacks contributed to its decline; the legitimate value has not yet materialized. For now the profit flows to the unregulated end, not to a proven medicine.
Where the research comes from
Most of the published research on this comes from one place. 54% of it is from USA. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| USA | 54% |
| Japan | 24% |
| South Korea | 12% |
| Other | 10% |
Research published from: USA, Japan, South Korea.
How we got here
MOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered around 2015 by Changhan Lee in the Pinchas Cohen laboratory at the USC Leonard Davis School of Gerontology. It is encoded within the mitochondrial 12S rRNA (MT-RNR1) region and acts as an exercise-mimetic regulator of glucose metabolism and insulin sensitivity. It circulates in a gray-market research-peptide form, distinct from CB4211, the improved MOTS-c analog that CohBar advanced through Phase 1a/1b clinical trials for NASH and obesity.
MOTS-c emerged from a new field. After humanin was identified in 2003 as the first mitochondrial-derived peptide, researchers led by Pinchas Cohen’s group characterized MOTS-c in 2015, showing that a peptide encoded in mitochondrial DNA could act as a hormone-like metabolic signal and regulate nuclear genes. Its exercise-mimetic and anti-aging profile quickly made it a longevity and biohacking favorite. The biotech CohBar pursued mitochondrial-derived peptide drugs, including a MOTS-c analog, but clinical setbacks led to the program’s end, and as of 2026 MOTS-c remains an investigational molecule with human metabolic trials in progress.
Discovery
2015 to 2015
MOTS-c is characterized as a mitochondrial-derived peptide in metabolic models.
- 2015MOTS-c is characterizedThe discovery paper described a 16-amino-acid mitochondria-encoded peptide that activated AMPK-related signaling and improved metabolic measures in mice.
- 2015CohBar Investigation beginsCohBar announced the Cell Metabolism publication describing MOTS-c. It stated that it held an exclusive, worldwide license to develop MOTS-c into therapeutics, and it named the senior author, Pinchas Cohen, as CohBar's founder and director.
Translation research
2017 to 2021
Patents explored analogues while human work measured endogenous MOTS-c rather than treatment.
- 2017CohBar files a patent application for modified MOTS-c-related peptidesThe application covers analogues selected partly through mouse-plasma testing; it does not establish native MOTS-c vial stability.
- 2021Exercise-linked MOTS-c changes are measured in peopleThe study measured the body's own MOTS-c response to exercise in humans and separately tested injected MOTS-c in aged mice. It was not a human treatment trial.
Compounding review, 2026
From 2026
- July 2026A company press release reports that the FDA Pharmacy Compounding Advisory Committee recommended six peptide substances, MOTS-c among them, for the 503A Bulks List. It describes the recommendation as advisory, with final authority left to the FDA.
The numbers behind the grade
- Type
- Mitochondrial peptide
- Size
- 16 amino acids
- Mechanism
- AMPK activation
- Discovered
- 2015
- Approved
- No
- Human evidence
- Early
The people taking it
The audience is the biohacking and longevity crowd: people focused on metabolic health, insulin sensitivity and healthy aging, plus athletes drawn to the exercise-mimetic idea. These are the visible communities a gray market shows.
A buzzy favorite of the biohacking and longevity world, widely dubbed "exercise in a bottle," and one of the most-discussed mitochondrial-derived peptides, used well ahead of the human evidence.
MOTS-c users are concentrated in the biohacking and longevity world: people focused on metabolic health, insulin sensitivity and healthy aging, plus performance-minded athletes drawn to the exercise-mimetic idea. The audience skews toward the optimization crowd rather than patients with a diagnosed condition, and as with all gray-market peptides there is no reliable demographic data, only the visible communities organized around metabolic and longevity protocols.
Used gray-market for metabolic health, insulin sensitivity, performance and longevity, almost entirely outside approved medicine. Athletes should treat it as prohibited. Its standing rests on strong preclinical data and early human research.
Set against the alternatives
MOTS-c is best judged against the things it is compared to. Against exercise, it reproduces some signaling but not the whole adaptation, so it complements rather than replaces training. Against metformin, which also converges on AMPK and is approved, cheap and proven for glucose control, MOTS-c is unproven and unapproved, so metformin remains the evidence-based choice for metabolic goals. Against the other mitochondrial-derived peptides, humanin and SS-31 lean cytoprotective and neuroprotective while MOTS-c is the metabolic one. And against GLP-1 drugs, the mechanism is entirely different: MOTS-c works through mitochondrial energy signaling, not appetite. Its distinction is novelty and rationale; its weakness is the absence of human proof.
What we do not know
- Whether the strong animal metabolic effects translate into meaningful, consistent benefits in humans, which current trials aim to answer.
- Whether MOTS-c does anything that exercise or approved drugs like metformin do not.
- What its long-term safety is in people.
- Whether the nuclear, gene-regulating mechanism operates as proposed in human tissue at practical doses.
- Whether any developer can succeed where CohBar did not in turning the biology into a drug.
What could change
Human metabolic trialsOngoing studies in insulin sensitivity, glucose and fatty liver will decide whether the animal promise holds.Mitochondrial-derived peptide biologyBroader interest in MDPs as a new signaling class continues to grow.A viable drugWhether any developer succeeds where CohBar did not is the key commercial question.Aging applicationsIts decline with age keeps it prominent in longevity research.
Legal status
MOTS-c is not approved or available as a therapeutic anywhere. It is sold gray-market as research-use-only material and used within some longevity and metabolic clinics, neither of which is an approved medical route. Human trials are underway but have not established it as safe or effective. As an unapproved metabolic modulator and exercise mimetic, it should be treated as prohibited in sport. The evidence-based routes to its goals remain exercise and, where appropriate, approved metabolic drugs.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
There is no approved way to buy MOTS-c as a medicine. It is available only as research-use-only material from online vendors, which is not for human use, or through longevity clinics operating in a gray zone. For the metabolic benefits people seek, exercise and approved drugs like metformin are the proven alternatives; anyone using MOTS-c should at minimum insist on a third-party certificate of analysis.
Gray-market research vials are inexpensive per milligram, which fuels casual experimentation. Clinic-based programs cost more once consultations and markups are added. As always, the low price of a research vial comes with no assurance of identity, dose or purity.
Essentially all consumer MOTS-c is synthesized in China and sold as research material, with no guarantee of what the vial contains. A current third-party certificate of analysis is the only meaningful check, and even that does not substitute for the controls a real drug would undergo.
ChinaThe dominant source of MOTS-c as research-use-only material, synthesized and sold online worldwide.Research vendors and clinicsDomestic resellers and longevity clinics distribute it as a research chemical or within metabolic and anti-aging programs.No approved supplyBecause there is no approved product, there is no regulated, traceable pharmaceutical chain for it.
At a glance
- Amino acid sequence
- MRWQEMGYIFYPRKLR
- Amino acids
- 16
- Encoded in
- Mitochondrial 12S rRNA
- Activates
- AMPK (exercise pathway)
- Trend
- Levels rise w/ exercise, fall w/ age
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about MOTS-c.
Nothing outstanding on this one.
Sources
Discovery of MOTS-c: 16-aa mitochondrial-derived peptide activates AMPK and reduces diet-induced obesity and insulin resistance in mice (animal/in-vitro, not human)
In the 2021 Nature Communications study, MOTS-c improved physical performance across young, middle-aged, and old mice, and altered the activity of genes in the cell nucleus tied to metabolism and protein upkeep while shifting how mouse skeletal muscle handled glucose and amino acids. Exercise induces endogenous MOTS-c in human skeletal muscle and circulation, though human evidence remains observational.
Reynolds JC, Lee C, et al. Nature Communications 2021 (USC Lee Lab)
Open-access confirmation of the 2021 exercise/aging MOTS-c paper text and figures (USC Benayoun/Lee)
Hudson Biotech sponsored NCT07505745, a Phase 2a randomized double-blind placebo-controlled trial of MOTS-c in adults with prediabetes and overweight or obesity, with a primary endpoint of OGTT-derived insulin sensitivity measured by Matsuda index in approximately 120 subjects, and enrollment was not completed at the time of reporting.
MOTS-c is prohibited by WADA at all times under S4.4 metabolic modulators as an AMPK activator; no medical exemption available because there is no approved medical use
AMPK activators including MOTS-c are prohibited by WADA under S4 hormone and metabolic modulators, banned in and out of competition
MOTS-c is not FDA approved for any indication, is banned by WADA, and is used off-label as a research-chemical injectable despite a lack of robust human data
Independent scientific appraisal: MOTS-c evidence is preclinical (rodent/in-vitro), no completed human clinical trials, safety in humans unknown
Alzheimer's Drug Discovery Foundation, Cognitive Vitality MOTS-c report
Review of MOTS-c in diabetes and aging-related disease, summarizing mechanistic and animal evidence and the mitochondrial-derived-peptide concept
A 2021 study in the American Journal of Physiology Endocrinology and Metabolism reports that people with higher blood levels of MOTS-c tended to have lower blood levels of myostatin, a protein that limits muscle growth, though this is a correlation rather than a treatment result. In preclinical models and lab-grown muscle cells, MOTS-c reduced myostatin and muscle-atrophy signaling and prevented cell shrinkage caused by the fatty acid palmitic acid. The study proposes that MOTS-c may work through a signaling chain in muscle by raising the activity of the enzyme CK2, which holds back the protein PTEN, while also raising mTORC2 activity; together these changes act on AKT, a protein that helps control muscle growth and breakdown, though these steps come from animal and cell work rather than human studies.
CohBar filed this application in 2017 for modified MOTS-c-related peptides. Some covered analogues were defined by mouse-plasma stability criteria, but this does not establish native MOTS-c vial or storage stability.
A patent reports a 44-rat Parkinson-like experiment in which injected MOTS-c was associated with better movement measures, lower oxidative-stress markers, and stronger dopamine-related signals. This is patent-reported animal evidence, not a human trial.
CN113876929A. Application of peptide MOTS-c in preparation of a drug for treating Parkinson disease.
The 2015 discovery paper reports that MOTS-c is made from a short stretch of genetic code inside the mitochondrial 12S rRNA gene. Its name stands for mitochondrial open reading frame of the 12S rRNA-c.
A review of mitochondrial-derived peptides proposes that skeletal muscle is a major target of the MOTS-c that circulates in the blood. It adds that experimental evidence also points to fat cells as a possible target.
MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism (PMC5116416)
A 2023 review in Metabolites describes MOTS-c as working mainly through the AICAR-AMPK signaling pathway, by disrupting the folate-methionine cycle inside cells.
A 2018 cell study reports that MOTS-c, which is made in the mitochondria, moves into the cell nucleus when cells are under metabolic stress. The move depends on AMPK.
A 2026 lab study in Inflammation and Regeneration took mesenchymal stromal cells, a type of repair cell, from the belly fat of six donors with obesity (BMI 30 or higher) and six lean donors. The cells were treated with MOTS-c in the dish and checked for growth, markers of cell aging (p16 and p21), the inflammatory signal TNF-alpha, and antioxidant genes. No person was given MOTS-c.
A 2025 study in Experimental and Molecular Medicine reports that MOTS-c levels fall with aging and cell senescence in mouse pancreatic islet cells, and treating islets from old mice with MOTS-c reduced signs of senescence. The study also found that circulating MOTS-c levels are lower in people with type 2 diabetes than in healthy controls, though the type 2 diabetes group was older, making it unclear whether the difference reflects aging, diabetes, or both.
A 2024 iScience study reports that MOTS-c binds directly to the enzyme CK2 and activates it in cell-free tests and in mice, where it raised CK2 activity in muscle while lowering it in fat by altering which partner proteins attached to CK2 in each tissue. In mice, MOTS-c prevented skeletal muscle wasting and increased glucose uptake by muscle. A natural variant, K14Q MOTS-c, bound CK2 less effectively and did not activate it; in human genetic data, men carrying this variant showed associations with higher risk of sarcopenia and type 2 diabetes depending on age and physical activity, while women carrying it showed associations with lower type 2 diabetes risk at certain ages.
MOTS-c modulates skeletal muscle function by directly binding and activating CK2 - PMC
A 2021 Cell Reports study found that MOTS-c treatment in nonobese diabetic mice, a model of autoimmune type 1 diabetes, delayed disease onset, reduced high blood sugar, and cut the number of immune cells entering the pancreatic islets by raising regulatory T cells and lowering Th1 cells in the spleen and pancreas. The authors report that MOTS-c binds Raptor, part of the mTORC1 complex, and works partly by holding back mTORC1 signaling in T cells. In the human part of the study involving people with type 1 diabetes, blood MOTS-c levels tracked the metabolic state of CD4+ T cells, though this was a measurement rather than a treatment outcome.
Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes - PubMed
A 2021 study in a mouse model of gestational diabetes created with a short high-fat diet plus low-dose streptozotocin found that daily MOTS-c during pregnancy lowered high blood sugar, improved insulin sensitivity and glucose tolerance, and reduced the extra birth weight and offspring deaths caused by gestational diabetes. This study treated pregnant mice, not pregnant people.
An FDA briefing document for the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting reports that FDA proposed leaving MOTS-c free base and MOTS-c acetate off the Section 503A bulks list. The briefing was written before the meeting and does not record how the committee voted.
In its presentation to the July 23-24, 2026 Pharmacy Compounding Advisory Committee, FDA said it found no publicly available studies that gave MOTS-c free base or MOTS-c acetate to people. The presentation does not record how the committee later voted.
July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) Meeting
WADA's 2026 Prohibited List places activators of AMPK among the metabolic modulators in section S4, Hormone and Metabolic Modulators, which are prohibited at all times, in and out of competition. This attempt did not confirm whether the 2026 list names MOTS-c itself.
The studies that matter
Lee et al, discovery paper2015
Identified and characterized MOTS-c, and showed that treated mice on high-fat diets maintained markedly better glucose control, establishing it as a metabolic regulator.
AMPK/AICAR mechanism studies2015-2020s
Worked out that MOTS-c activates AMPK by inhibiting the folate cycle and de novo purine synthesis, causing the endogenous AMPK activator AICAR to build up.
Aging and exercise studies2010s-2020s
Circulating MOTS-c falls with age (around 20% lower in one human study); aged mice given MOTS-c regained metabolic flexibility and physical performance.
CohBar CB4211 (MOTS-c analog)early 2020s
A clinical-stage MOTS-c-based analog for obesity and fatty liver did not clearly meet its endpoints, and the program was discontinued, a cautionary commercial data point.
Human metabolic trialsongoing
Trials in healthy volunteers and in people with obesity and fatty liver are testing insulin sensitivity and related endpoints; results will determine whether the animal promise translates.